Article

A kinome-wide CRISPR screen identifies CK1α as a novel target to overcome enzalutamide resistance of prostate cancer

2022-05-18

Abstract excerpt

<title>Abstract</title> <p>Enzalutamide (ENZA), a second-generation androgen receptor antagonist, has significantly increased progression-free and overall survival of patients with metastatic prostate cancer (PCa). However, resistance remains a prominent obstacle in treatment, illustrating the urgent need to develop new approaches to increase ENZA efficacy. Utilizing a kinome-wide CRISPR-Cas9 knockout screen, we...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 7e1850c8-4143-523f-8672-32348603bfe5
DOI: 10.21203/rs.3.rs-1450886/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

A kinome-wide CRISPR screen identifies CK1α as a novel target to overcome enzalutamide resistance of prostate cancerDOI 10.21203/rs.3.rs-1450886/v1Read

A kinome-wide CRISPR screen identifies CK1α as a target to overcome enzalutamide resistance of prostate cancerSemantic proximity Read

A kinome-centered CRISPR-Cas9 screen identifies activated BRAF to modulate enzalutamide resistance with potential therapeutic implications in BRAF-mutated prostate cancer.Semantic proximity Read

Metabolic CRISPR screening identifies RPE as a key regulator of acquired enzalutamide resistance through FKBP5 destabilization in prostate cancer.Semantic proximity Read

CRISPR screening identifies CDK12 as a conservative vulnerability of prostate cancerSemantic proximity Read

CKS1B as Drug Resistance-Inducing Gene—A Potential Target to Improve Cancer TherapySemantic proximity Read

CRISPR/Cas9 model of prostate cancer identifies Kmt2c deficiency as a metastatic driver by Odam/Cabs1 gene cluster expressionSemantic proximity Read

FOXA1 knock-out via CRISPR/Cas9 altered Casp-9, Bax, CCND1, CDK4, and fibronectin expressions in LNCaP cells.Semantic proximity Read

Kinesin Facilitates Phenotypic Targeting of Therapeutic Resistance in Advanced Prostate Cancer.Semantic proximity Read

Novel inhibition of AKR1C3 and androgen receptor axis by PTUPB synergizes enzalutamide treatment in advanced prostate cancerSemantic proximity Read

A synthetic lethal dependency on casein kinase 2 in response to replication-perturbing drugs in RB1-deficient ovarian and breast cancer cellsSemantic proximity Read

Developing a Novel Enzalutamide-Resistant Prostate Cancer Model via AR F877L Mutation in LNCaP Cells.Semantic proximity Read

CRISPR screens reveal genetic determinants of PARP inhibitor sensitivity and resistance in prostate cancerSemantic proximity Read